Esperion Therapeutics (ESPR) Net Margin (2019 - 2026)
Esperion Therapeutics (ESPR) posted Net Margin of 32.93% for Q1 2026, down 188.62% on a QoQ basis from 37.16% in Q4 2025, and up 3096.0% year-over-year from 1.03% in Q1 2025.
Esperion Therapeutics (ESPR) Net Margin (2019 - 2026) Analysis & Trends
Esperion Therapeutics' Net Margin history runs 8 years deep, the most recent figure standing at 32.93% for Q1 2026.
- Quarterly Net Margin rose 3096.0% year-over-year to 32.93% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.2% (up 4128.0% YoY) and the FY2025 annual result came in at 5.63%, up 994.0% from the prior year.
- Net Margin was 32.93% for Q1 2026 at Esperion Therapeutics, down from 37.16% in the prior quarter.
- Across five years, Net Margin topped out at 42.29% in Q1 2024 and bottomed at 353.71% in Q2 2022.
- A 5-year average of 129.56% and a median of 63.89% in 2025 frame the typical range for Net Margin.
- Peak annual rise in Net Margin reached 83711 bps in 2022, while the deepest fall reached 24628 bps in 2022.
- Esperion Therapeutics' Net Margin stood at 302.06% in 2022, then soared by 41 bps to 178.06% in 2023, then soared by 76 bps to 42.07% in 2024, then soared by 188 bps to 37.16% in 2025, then tumbled by 189 bps to 32.93% in 2026.
- Business Quant data shows ESPR's Net Margin at 32.93% in Q1 2026, 37.16% in Q4 2025, and 36.66% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 9.29% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 26.57% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -33.66% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 35.18% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 5.03% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 24.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 4.16% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -32.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.93% |
| Dec 31, 2025 | 37.16% |
| Sep 30, 2025 | -36.66% |
| Jun 30, 2025 | -16.25% |
| Mar 31, 2025 | -63.89% |
| Dec 31, 2024 | -42.07% |
| Sep 30, 2024 | -60.25% |
| Jun 30, 2024 | -15.09% |
| Mar 31, 2024 | 42.29% |
| Dec 31, 2023 | -178.06% |
| Sep 30, 2023 | -125.20% |
| Jun 30, 2023 | -200.09% |
| Mar 31, 2023 | -258.92% |
| Dec 31, 2022 | -302.06% |
| Sep 30, 2022 | -293.87% |
| Jun 30, 2022 | -353.71% |
| Mar 31, 2022 | -302.88% |
| Dec 31, 2021 | -448.40% |
| Sep 30, 2021 | -481.64% |
| Jun 30, 2021 | -107.42% |